Sarepta Therapeutics/$SRPT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Primary listing
Employees
1,372
Headquarters
Website
SRPT Metrics
BasicAdvanced
$2.3B
-
-$2.77
0.52
-
Price and volume
Market cap
$2.3B
Beta
0.52
52-week high
$129.84
52-week low
$10.42
Average daily volume
5.2M
Financial strength
Current ratio
2.954
Quick ratio
1.353
Long term debt to equity
94.703
Total debt to equity
95.473
Interest coverage (TTM)
-4.68%
Profitability
EBITDA (TTM)
-36.284
Gross margin (TTM)
18.39%
Net profit margin (TTM)
-11.25%
Operating margin (TTM)
-3.56%
Effective tax rate (TTM)
-7.66%
Revenue per employee (TTM)
$1,760,000
Management effectiveness
Return on assets (TTM)
-1.52%
Return on equity (TTM)
-21.37%
Valuation
Price to revenue (TTM)
0.904
Price to book
1.77
Price to tangible book (TTM)
1.81
Price to free cash flow (TTM)
-5.609
Free cash flow yield (TTM)
-17.83%
Free cash flow per share (TTM)
-3.968
Growth
Revenue change (TTM)
47.15%
Earnings per share change (TTM)
-327.17%
3-year revenue growth (CAGR)
40.19%
10-year revenue growth (CAGR)
212.70%
3-year earnings per share growth (CAGR)
-30.41%
10-year earnings per share growth (CAGR)
-5.40%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
SRPT News
AllArticlesVideos
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk
Benzinga2 weeks ago
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Business Wire2 weeks ago
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $2.3B as of December 06, 2025.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 0 as of December 06, 2025.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of December 06, 2025.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.